An injectable form of nivolumab has been successful in clinical trials for the treatment of kidney cancer. The injectable form of the drug allows large volumes of nivolumab, currently administered intravenously, to be delivered as an injection under the skin.

This new option for giving nivolumab as a single injection administered in less than five minutes, could transform the treatment experience for both patients and doctors, and do away with the regular visits to hospital for infusions.

This new form of nivolumab is yet to be approved for use in the UK by the regulators.

Read the press release here